{"product_id":"cst-76889s","title":"CST,  76889S, RVX-208","description":"Chemical Modulators for studying in the research area.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nRVX-208 is supplied as a lyophilized powder. For a 20 mM stock, reconstitute 10 mg of powder in 1.35 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.\n\u003cb\u003eStorage\u003c\/b\u003e\nStore lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze\/thaw cycles.\n\u003cb\u003eBackground\u003c\/b\u003e\nRVX-208 is a potent and selective inhibitor of bromodomain and extra terminal (BET) proteins, with a much stronger affinity for BD2 (IC = 0.510 μM) over BD1 (IC = 87 μM) (1,2). BET proteins interact with acetylated lysine-containing sequences to transcriptionally regulate several cellular processes. BRD4, a BET protein that mediates induction of Apolipoprotein A-I (ApoA-I) mRNA, can be disrupted at the binding site by RVX-208. This leads to altered transcription, resulting in increased ApoA-I production and high-density lipoprotein cholesterol (HDL-C) levels, both of which are promising in the treatment of atherosclerosis and vascular inflammation (2-4). Recently, BRD4 inhibition has shown anti-viral activity and increased host resistance to several DNA and RNA viruses and , making BRD4 disruptors important compounds to study in relation to viral diseases (5).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\n2-[4-2-hydroxyethoxy-35-dimethylphenyl]-57-dimethoxy-43H-quinazolinone","brand":"CST","offers":[{"title":"Default Title","offer_id":46800698343593,"sku":"76889S","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-76889s","provider":"Iright","version":"1.0","type":"link"}